Biomarker & Intervention Discovery

Lung Cancer

This page lists 12 druggable gene targets, 52 approved or trial-tested drug candidates and 15 recent clinical trials for Lung Cancer, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Plain-language summary → New Treatments for Lung Cancer (2026): Drugs in Trials

US DALYs3.04MWHO GHE 2021 · all ages
Global DALYs45.38MWHO GHE 2021 · worldwide
US mortality137.1K deaths/yrWHO GHE 2021
Global mortality1.85M deaths/yrWHO GHE 2021 · worldwide
NIH funding$439MFY2025 · RCDC estimate
Funding levelUnderfunded
Spontaneous remissionSpontaneous regression is rare (<0.5% of cases); 5-year survival without treatment: <5% for advanced NSCLC; ~20% for…
Best-intervention remissionNSCLC with driver mutations (EGFR, ALK, ROS1, MET, KRAS G12C): targeted therapy achieves 70-90% response rates; PFS…
Gap sizeVery large between targeted/immunotherapy eligible and chemotherapy-only; large between treated and screened populations
Primary barrieraccess/practice
Full remission profile →
Research Tracker Chronic Disease Interventions Lung Cancer

Remission & chronicity

Spontaneous remission
Spontaneous regression is rare (<0.5% of cases); 5-year survival without treatment: <5% for advanced NSCLC; ~20% for stage I-II with surgery
Best-intervention remission
NSCLC with driver mutations (EGFR, ALK, ROS1, MET, KRAS G12C): targeted therapy achieves 70-90% response rates; PFS 16-19 months with osimertinib (FLAURA2 combination up to 25 months); immunotherapy (pembrolizumab): 5-year OS ~31% in high PD-L1 expressers vs ~16% chemotherapy; SBRT for early-stage inoperable: 80-90% local control at 3 years
Gap size
Very large between targeted/immunotherapy eligible and chemotherapy-only; large between treated and screened populations
Primary barrier
access/practice
Biomarker testing (PD-L1, EGFR/ALK/ROS1 mutations) still not universal; only 5-6% of high-risk smokers undergo low-dose CT screening despite 20% mortality reduction (NLST trial); smoking cessation dramatically reduces incidence but is underfunded

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

ALK 278BRAF 361CD274 200EGFR 403ERBB2 336KDR 382KRAS 233MET 299NTRK1 256PDCD1 52RET 233ROS1 214

ALK

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
HESPERADIN ↓ inhibits Mechanistic DGIdb
ENSARTINIB ↓ inhibits Mechanistic DGIdb
BRIGATINIB ↓ inhibits Mechanistic DGIdb
EG5 KINESIN-RELATED MOTOR PROTEIN INHIBITOR 4SC-205 ? unclear Mechanistic DGIdb
CRIZOTINIB ↓ inhibits Mechanistic 20.0 nM (IC50) DGIdb
CARBAMAZEPINE ? unclear Mechanistic DGIdb
FILGOTINIB ? unclear Mechanistic DGIdb
UNECRITINIB ↓ inhibits Mechanistic DGIdb
ALECTINIB ↓ inhibits Mechanistic DGIdb
BELIZATINIB ↓ inhibits Mechanistic DGIdb
AFATINIB ? unclear Mechanistic DGIdb
ERLOTINIB ? unclear Mechanistic 1200.0 nM (Kd) DGIdb
TAMATINIB ? unclear Mechanistic DGIdb
IPILIMUMAB ? unclear Mechanistic DGIdb
CEP-37440 ↓ inhibits Mechanistic DGIdb
ETOPOSIDE ? unclear Mechanistic DGIdb
CONTELTINIB ? unclear Mechanistic DGIdb
NVP-TAE 226 ? unclear Mechanistic DGIdb
PEMBROLIZUMAB ? unclear Mechanistic DGIdb
IDASANUTLIN ? unclear Mechanistic DGIdb
BRENTUXIMAB VEDOTIN ? unclear Mechanistic DGIdb
IMATINIB ? unclear Mechanistic DGIdb
TAK-715 ? unclear Mechanistic DGIdb
ENTRECTINIB ↓ inhibits Mechanistic DGIdb
NIVOLUMAB ? unclear Mechanistic DGIdb
PD166285 ? unclear Mechanistic DGIdb
AZD3463 ↓ inhibits Mechanistic DGIdb
CEMIPLIMAB ? unclear Mechanistic DGIdb
CYTARABINE ? unclear Mechanistic DGIdb
REPOTRECTINIB ↓ inhibits Mechanistic DGIdb
DABRAFENIB ? unclear Mechanistic DGIdb
VANDETANIB ? unclear Mechanistic 2100.0 nM (Kd) DGIdb
ALK/C-MET INHIBITOR TQ-B3139 ? unclear Mechanistic DGIdb
COMPOUND 17 [PMID: 34176264] ↓ inhibits Mechanistic DGIdb
ZOLEDRONIC ACID ANHYDROUS ? unclear Mechanistic DGIdb
CERITINIB ↓ inhibits Mechanistic DGIdb
ENVONALKIB ↓ inhibits Mechanistic DGIdb
TOPOTECAN HYDROCHLORIDE ? unclear Mechanistic DGIdb
FULVESTRANT ? unclear Mechanistic DGIdb
MTI-31 ? unclear Mechanistic DGIdb

Showing top 40 of 278 agents ranked by evidence tier.

BRAF

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ENZALUTAMIDE ? unclear Mechanistic DGIdb
AVUTOMETINIB ? unclear Mechanistic DGIdb
TRAMETINIB DIMETHYL SULFOXIDE ? unclear Mechanistic DGIdb
NIVOLUMAB ? unclear Mechanistic DGIdb
LIFIRAFENIB ↓ inhibits Mechanistic DGIdb
BINIMETINIB ? unclear Mechanistic DGIdb
SORAFENIB ↓ inhibits Mechanistic 46.0 nM (IC50) DGIdb
CI-1040 ? unclear Mechanistic DGIdb
NAVITOCLAX ? unclear Mechanistic DGIdb
OMIPALISIB ? unclear Mechanistic DGIdb
ALPELISIB ? unclear Mechanistic DGIdb
B-RAF/VEGFR-2 INHIBITOR RAF265 ↓ inhibits Mechanistic DGIdb
REGORAFENIB ↓ inhibits Mechanistic DGIdb
SARACATINIB ? unclear Mechanistic DGIdb
PONATINIB ? unclear Mechanistic DGIdb
ERLOTINIB ? unclear Mechanistic DGIdb
MEK INHIBITOR IMM-1-104 ? unclear Mechanistic DGIdb
COMPOUND 2 [PMID: 26061392] ↓ inhibits Mechanistic DGIdb
PANITUMUMAB ? unclear Mechanistic DGIdb
CHIR-265 ↓ inhibits Mechanistic DGIdb
MIRDAMETINIB ? unclear Mechanistic DGIdb
SB590885 ↓ inhibits Mechanistic 0.3 nM (Kd) DGIdb
KO-947 ? unclear Mechanistic DGIdb
BUPARLISIB ? unclear Mechanistic DGIdb
TOVORAFENIB ↓ inhibits Mechanistic DGIdb
ATEZOLIZUMAB ? unclear Mechanistic DGIdb
AZD1208 ? unclear Mechanistic DGIdb
PI3K/BET INHIBITOR LY294002 ? unclear Mechanistic DGIdb
GEDATOLISIB ? unclear Mechanistic DGIdb
DOXORUBICIN LIPOSOME ? unclear Mechanistic DGIdb
DABRAFENIB ↓ inhibits Mechanistic DGIdb
FUTIBATINIB ? unclear Mechanistic DGIdb
SAR260301 ? unclear Mechanistic DGIdb
SONOLISIB ? unclear Mechanistic DGIdb
BRAFV600/PI3K INHIBITOR ASN003 ? unclear Mechanistic DGIdb
IDELALISIB ? unclear Mechanistic DGIdb
E6201 ? unclear Mechanistic DGIdb
SAPITINIB ? unclear Mechanistic DGIdb
OXALIPLATIN ? unclear Mechanistic DGIdb
DENOSUMAB ? unclear Mechanistic DGIdb

Showing top 40 of 361 agents ranked by evidence tier.

CD274

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ATEZOLIZUMAB ? unclear Mechanistic DGIdb
DURVALUMAB ↓ inhibits Mechanistic DGIdb
PEMETREXED DISODIUM ? unclear Mechanistic DGIdb
BETIFISOLIMAB ? unclear Mechanistic DGIdb
AVELUMAB ? unclear Mechanistic DGIdb
SOCAZOLIMAB ↓ inhibits Mechanistic DGIdb
NIVOLUMAB ? unclear Mechanistic DGIdb
COSIBELIMAB ? unclear Mechanistic DGIdb
DANBURSTOTUG ↓ inhibits Mechanistic DGIdb
ENVAFOLIMAB ? unclear Mechanistic DGIdb
PACMILIMAB ~ modulates Mechanistic DGIdb
CA-170 ? unclear Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
TISLELIZUMAB ? unclear Mechanistic DGIdb
ERFONRILIMAB ↓ inhibits Mechanistic DGIdb
TREMELIMUMAB ? unclear Mechanistic DGIdb
ANTI-PD-L1 MONOCLONAL ANTIBODY FAZ053 ? unclear Mechanistic DGIdb
BINTRAFUSP ALFA ? unclear Mechanistic DGIdb
IPILIMUMAB ? unclear Mechanistic DGIdb
CEMIPLIMAB ? unclear Mechanistic DGIdb
ADEBRELIMAB ↓ inhibits Mechanistic DGIdb
SUGEMALIMAB ~ modulates Mechanistic DGIdb
LODAPOLIMAB ? unclear Mechanistic DGIdb
INCB-086550 ↓ inhibits Mechanistic DGIdb
PIDILIZUMAB ? unclear Mechanistic DGIdb
CARBOPLATIN ? unclear Mechanistic DGIdb
ANTI-PD-L1 MONOCLONAL ANTIBODY MDX-1105 ? unclear Mechanistic DGIdb
PENPULIMAB ? unclear Mechanistic DGIdb
PEMBROLIZUMAB ? unclear Mechanistic DGIdb
ANTI-LAG-3/PD-L1 BISPECIFIC ANTIBODY FS118 ? unclear Mechanistic DGIdb
CHEMBL3582257 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL3582256 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL3582255 ↓ inhibits Mechanistic 1010.0 nM (IC50) ChEMBL
CHEMBL3582254 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL3582253 ↓ inhibits Mechanistic 110.0 nM (IC50) ChEMBL
CHEMBL3582252 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL4081869 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL4099869 ↓ inhibits Mechanistic 146.0 nM (IC50) ChEMBL
CHEMBL4089730 ↓ inhibits Mechanistic 18.0 nM (IC50) ChEMBL
CHEMBL4061613 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL

Showing top 40 of 200 agents ranked by evidence tier.

EGFR

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
AUMOLERTINIB ↓ inhibits Mechanistic DGIdb
AFATINIB ↓ inhibits Mechanistic DGIdb
ABIVERTINIB ↓ inhibits Mechanistic DGIdb
FUTUXIMAB ↓ inhibits Mechanistic DGIdb
RINDOPEPIMUT ? unclear Mechanistic DGIdb
PD-0166285 HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
OLMUTINIB ↓ inhibits Mechanistic DGIdb
OSIMERTINIB MESYLATE ↓ inhibits Mechanistic DGIdb
ABIVERTINIB MALEATE ↓ inhibits Mechanistic DGIdb
ROCILETINIB ↓ inhibits Mechanistic DGIdb
GEFITINIB ↓ inhibits Mechanistic 515.0 nM (IC50) DGIdb
MATUZUMAB ↓ inhibits Mechanistic DGIdb
GRACILIN J ? unclear Mechanistic DGIdb
NIMOTUZUMAB ↓ inhibits Mechanistic DGIdb
LAZERTINIB ↓ inhibits Mechanistic DGIdb
LAPATINIB ↓ inhibits Mechanistic DGIdb
PANITUMUMAB ↓ inhibits Mechanistic DGIdb
DOSIMERTINIB ↓ inhibits Mechanistic DGIdb
COMPOUND 17B [PMID: 35286086] ↓ inhibits Mechanistic DGIdb
IBRUTINIB ↓ inhibits Mechanistic DGIdb
POZIOTINIB ↓ inhibits Mechanistic DGIdb
TARLOXOTINIB ↓ inhibits Mechanistic DGIdb
OSIMERTINIB ↓ inhibits Mechanistic DGIdb
DACOMITINIB ANHYDROUS ↓ inhibits Mechanistic DGIdb
ICOTINIB HYDROCHLORIDE ? unclear Mechanistic DGIdb
MIFANERTINIB ↓ inhibits Mechanistic DGIdb
NAQUOTINIB ↓ inhibits Mechanistic DGIdb
BMS-690514 ↓ inhibits Mechanistic DGIdb
NAZARTINIB ↓ inhibits Mechanistic DGIdb
CUDC-101 ↓ inhibits Mechanistic DGIdb
DEHYDRATED ALCOHOL ? unclear Mechanistic DGIdb
BEFOTERTINIB ↓ inhibits Mechanistic DGIdb
NECITUMUMAB ↓ inhibits Mechanistic DGIdb
CHEMBL:CHEMBL1914653 ? unclear Mechanistic DGIdb
LAPRITUXIMAB EMTANSINE ? unclear Mechanistic DGIdb
INDIUM-111 ? unclear Mechanistic DGIdb
AV-412 ↓ inhibits Mechanistic DGIdb
CETUXIMAB ↓ inhibits Mechanistic DGIdb
EPIREGULIN ? unclear Mechanistic DGIdb

Showing top 40 of 403 agents ranked by evidence tier.

ERBB2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TYRPHOSTIN AG 879 ? unclear Mechanistic DGIdb
TAK-285 ↓ inhibits Mechanistic DGIdb
PERTUZUMAB ↓ inhibits Mechanistic DGIdb
SAPITINIB ↓ inhibits Mechanistic DGIdb
CANERTINIB ↓ inhibits Mechanistic 529.0 nM (IC50) DGIdb
LAPATINIB ↓ inhibits Mechanistic 9.0 nM (IC50) DGIdb
AFATINIB DIMALEATE ↓ inhibits Mechanistic DGIdb
MUBRITINIB ↓ inhibits Mechanistic DGIdb
JNJ-26483327 ↓ inhibits Mechanistic DGIdb
NAKIJIQUINONE I ? unclear Mechanistic DGIdb
AEE788 ↓ inhibits Mechanistic DGIdb
HEMAY-022 ↓ inhibits Mechanistic DGIdb
MM-111 ? unclear Mechanistic DGIdb
NERATINIB ↓ inhibits Mechanistic DGIdb
DACOMITINIB ANHYDROUS ↓ inhibits Mechanistic DGIdb
IXABEPILONE ? unclear Mechanistic DGIdb
DIETHYLSTILBESTROL ? unclear Mechanistic DGIdb
TAMATINIB ? unclear Mechanistic DGIdb
S-222611 ↓ inhibits Mechanistic DGIdb
CP-724714 ? unclear Mechanistic DGIdb
AKT INHIBITOR MK2206 ? unclear Mechanistic DGIdb
ANTINEOPLASTIC AGENT ? unclear Mechanistic DGIdb
TIPIFARNIB ? unclear Mechanistic DGIdb
BMS-599626 ↓ inhibits Mechanistic DGIdb
MIFANERTINIB ↓ inhibits Mechanistic DGIdb
GEFITINIB ↓ inhibits Mechanistic 1604.0 nM (IC50) DGIdb
ADO-TRASTUZUMAB EMTANSINE ? unclear Mechanistic DGIdb
CARBOPLATIN ? unclear Mechanistic DGIdb
TRASTUZUMAB DUOCARMAZINE ~ modulates Mechanistic DGIdb
POZIOTINIB ↓ inhibits Mechanistic DGIdb
HLX22 ? unclear Mechanistic DGIdb
CURCUMIN ? unclear Mechanistic DGIdb
HSP90 INHIBITOR ? unclear Mechanistic DGIdb
TUCATINIB ↓ inhibits Mechanistic DGIdb
TRASTUZUMAB ↓ inhibits Mechanistic DGIdb
EPIGALLOCATECHIN GALLATE ? unclear Mechanistic DGIdb
PACLITAXEL PROTEIN-BOUND ? unclear Mechanistic DGIdb
FAM-TRASTUZUMAB DERUXTECAN-NXKI ? unclear Mechanistic DGIdb
DASATINIB ANHYDROUS ? unclear Mechanistic DGIdb
TRASTUZUMAB EMTANSINE ~ modulates Mechanistic DGIdb

Showing top 40 of 336 agents ranked by evidence tier.

KDR

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CEDIRANIB ↓ inhibits Mechanistic DGIdb
XL820 ↓ inhibits Mechanistic DGIdb
EUPATORIN ↓ inhibits Mechanistic DGIdb
CABOZANTINIB S-MALATE ↓ inhibits Mechanistic DGIdb
TOCERANIB ↓ inhibits Mechanistic DGIdb
LAZERTINIB ↓ inhibits Mechanistic DGIdb
VADIMEZAN ? unclear Mechanistic DGIdb
VANDETANIB ↓ inhibits Mechanistic 70.0 nM (IC50) DGIdb
SURUFATINIB ↓ inhibits Mechanistic DGIdb
CANLITINIB ↓ inhibits Mechanistic DGIdb
FORETINIB ↓ inhibits Mechanistic DGIdb
PEGPLERANIB SODIUM ? unclear Mechanistic DGIdb
REGORAFENIB ↓ inhibits Mechanistic DGIdb
LINIFANIB ↓ inhibits Mechanistic DGIdb
MOTESANIB ↓ inhibits Mechanistic DGIdb
ILORASERTIB ↓ inhibits Mechanistic DGIdb
SUNITINIB ↓ inhibits Mechanistic DGIdb
COMPOUND 13A [PMID: 23639540] ↓ inhibits Mechanistic DGIdb
PONATINIB ↓ inhibits Mechanistic DGIdb
XL-820 ↓ inhibits Mechanistic DGIdb
BX-795 ↓ inhibits Mechanistic DGIdb
TELATINIB ↓ inhibits Mechanistic DGIdb
SORAFENIB ↓ inhibits Mechanistic DGIdb
LUCITANIB ↓ inhibits Mechanistic DGIdb
PP-121 ↓ inhibits Mechanistic DGIdb
NINGETINIB ↓ inhibits Mechanistic DGIdb
TINENGOTINIB ↓ inhibits Mechanistic DGIdb
BJ-2412 ↓ inhibits Mechanistic DGIdb
VEGF RECEPTOR TYROSINE KINASE INHIBITOR III ↓ inhibits Mechanistic DGIdb
PF-00337210 ↓ inhibits Mechanistic DGIdb
AST-487 ↓ inhibits Mechanistic DGIdb
RAMUCIRUMAB ↓ inhibits Mechanistic DGIdb
AG-13958 ↓ inhibits Mechanistic DGIdb
SU-14813 ↓ inhibits Mechanistic DGIdb
X-82 ↓ inhibits Mechanistic DGIdb
ENMD-2076 ↓ inhibits Mechanistic DGIdb
GOLVATINIB ↓ inhibits Mechanistic DGIdb
CENISERTIB ? unclear Mechanistic DGIdb
LENVATINIB ↓ inhibits Mechanistic DGIdb
SULFATINIB ↓ inhibits Mechanistic DGIdb

Showing top 40 of 382 agents ranked by evidence tier.

KRAS

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
GEMCITABINE ? unclear Mechanistic DGIdb
VEDROPREVIR ↓ inhibits Mechanistic DGIdb
COBIMETINIB ? unclear Mechanistic DGIdb
BEVACIZUMAB ? unclear Mechanistic DGIdb
RAS PEPTIDE CANCER VACCINE ? unclear Mechanistic DGIdb
PACLITAXEL PROTEIN-BOUND ? unclear Mechanistic DGIdb
SOTORASIB ? unclear Mechanistic 68.0 nM (IC50) DGIdb
AMG410 ~ modulates Mechanistic DGIdb
NIVOLUMAB ? unclear Mechanistic DGIdb
PIMASERTIB ? unclear Mechanistic DGIdb
METFORMIN ? unclear Mechanistic DGIdb
TIZATERKIB ? unclear Mechanistic DGIdb
GARSORASIB ↓ inhibits Mechanistic DGIdb
CAPECITABINE ? unclear Mechanistic DGIdb
ENCORAFENIB ? unclear Mechanistic DGIdb
DACTOLISIB ? unclear Mechanistic DGIdb
IRINOTECAN HYDROCHLORIDE ? unclear Mechanistic DGIdb
PICTILISIB ? unclear Mechanistic DGIdb
PEMBROLIZUMAB ? unclear Mechanistic DGIdb
ARS-1620 ↓ inhibits Mechanistic DGIdb
DASATINIB ANHYDROUS ? unclear Mechanistic DGIdb
COMPOUND 25 [PMID: 32023060] ↓ inhibits Mechanistic DGIdb
DANOPREVIR ↓ inhibits Mechanistic DGIdb
DOCETAXEL ANHYDROUS ? unclear Mechanistic DGIdb
MUC1-TARGETED PEPTIDE GO-203-2C ? unclear Mechanistic DGIdb
THERAPEUTIC TUMOR INFILTRATING LYMPHOCYTES ? unclear Mechanistic DGIdb
AZACITIDINE ? unclear Mechanistic DGIdb
B-RAF/VEGFR-2 INHIBITOR RAF265 ? unclear Mechanistic DGIdb
PARITAPREVIR ↓ inhibits Mechanistic DGIdb
VANIPREVIR ↓ inhibits Mechanistic DGIdb
DUAL IGF-1R/INSR INHIBITOR BMS-754807 ? unclear Mechanistic DGIdb
SORAFENIB ? unclear Mechanistic DGIdb
CILUPREVIR ↓ inhibits Mechanistic DGIdb
TRASTUZUMAB ? unclear Mechanistic DGIdb
TEMSIROLIMUS ? unclear Mechanistic DGIdb
DECITABINE ? unclear Mechanistic DGIdb
SALIRASIB ↓ inhibits Mechanistic DGIdb
PHA-665752 ? unclear Mechanistic DGIdb
MITOGEN-ACTIVATED PROTEIN KINASE KINASE INHIBITOR ? unclear Mechanistic DGIdb
SELUMETINIB ↓ inhibits Mechanistic DGIdb

Showing top 40 of 233 agents ranked by evidence tier.

MET

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CABOZANTINIB S-MALATE ↓ inhibits Mechanistic DGIdb
GLESATINIB ↓ inhibits Mechanistic DGIdb
RIPK3 INHIBITOR 18 ↓ inhibits Mechanistic DGIdb
CENISERTIB ? unclear Mechanistic DGIdb
C-MET INHIBITOR AMG 337 ? unclear Mechanistic DGIdb
JNJ-38877605 ↓ inhibits Mechanistic DGIdb
TEREVALEFIM ↑ activates Mechanistic DGIdb
CRIZOTINIB ↓ inhibits Mechanistic 8.0 nM (IC50) DGIdb
ERLOTINIB ? unclear Mechanistic DGIdb
PF-562271 ? unclear Mechanistic DGIdb
ARRY-300 ↓ inhibits Mechanistic DGIdb
BMS-698769 ↓ inhibits Mechanistic DGIdb
MK-8033 ↓ inhibits Mechanistic DGIdb
DALMELITINIB ↓ inhibits Mechanistic DGIdb
SAVOLITINIB ↓ inhibits Mechanistic DGIdb
MK-2461 ↓ inhibits Mechanistic DGIdb
TELISOTUZUMAB VEDOTIN ~ modulates Mechanistic DGIdb
MERESTINIB ↓ inhibits Mechanistic DGIdb
ONARTUZUMAB ↓ inhibits Mechanistic DGIdb
COMPOUND R-16 [PMID: 21967808] ↓ inhibits Mechanistic DGIdb
EMIBETUZUMAB ↓ inhibits Mechanistic DGIdb
APRATOXIN F ? unclear Mechanistic DGIdb
YUANHUADINE ? unclear Mechanistic DGIdb
CAPMATINIB ↓ inhibits Mechanistic DGIdb
CAPMATINIB HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
TIVANTINIB ↓ inhibits Mechanistic DGIdb
SGX-523 ↓ inhibits Mechanistic DGIdb
ALTIRATINIB ↓ inhibits Mechanistic DGIdb
PAMUFETINIB ↓ inhibits Mechanistic DGIdb
BMS-777607 ↓ inhibits Mechanistic DGIdb
AMG-208 ↓ inhibits Mechanistic DGIdb
CP-547632 ? unclear Mechanistic DGIdb
ENSARTINIB ↓ inhibits Mechanistic DGIdb
SITRAVATINIB ↓ inhibits Mechanistic DGIdb
OSIMERTINIB ? unclear Mechanistic DGIdb
AMG-337 ↓ inhibits Mechanistic DGIdb
GALLOCATECHIN GALLATE ? unclear Mechanistic DGIdb
MITOGEN-ACTIVATED PROTEIN KINASE KINASE INHIBITOR ? unclear Mechanistic DGIdb
HEPATOCYTE GROWTH FACTOR ? unclear Mechanistic DGIdb
C-MET INHIBITOR MK2461 ↓ inhibits Mechanistic DGIdb

Showing top 40 of 299 agents ranked by evidence tier.

NTRK1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
THERAPEUTIC CYTOKINE ? unclear Mechanistic DGIdb
ENTRECTINIB ↓ inhibits Mechanistic DGIdb
MK-2461 ↓ inhibits Mechanistic DGIdb
GW843682X ? unclear Mechanistic DGIdb
ESTRADIOL VALERATE ? unclear Mechanistic DGIdb
CH7057288 ↓ inhibits Mechanistic DGIdb
LAROTRECTINIB ↓ inhibits Mechanistic DGIdb
GAMBOGIC ACID ? unclear Mechanistic DGIdb
PEGCANTRATINIB ? unclear Mechanistic DGIdb
WORTMANNIN ? unclear Mechanistic DGIdb
D5261 ~ modulates Mechanistic DGIdb
METHOTREXATE ? unclear Mechanistic DGIdb
UTATRECTINIB ↓ inhibits Mechanistic DGIdb
DOVITINIB ↓ inhibits Mechanistic 100.0 nM (Kd) DGIdb
TALETRECTINIB ↓ inhibits Mechanistic DGIdb
CEP-2563 DIHYDROCHLORIDE ? unclear Mechanistic DGIdb
GAMBOGIC AMIDE ? unclear Mechanistic DGIdb
SP-600125 ? unclear Mechanistic DGIdb
GAMMA-INTERFERON ? unclear Mechanistic DGIdb
MILCICLIB ↓ inhibits Mechanistic 53.0 nM (IC50) DGIdb
PHENYLEPHRINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
JNJ-28312141 ↓ inhibits Mechanistic DGIdb
DZX19 ↓ inhibits Mechanistic DGIdb
CYCLOPHOSPHAMIDE ANHYDROUS ? unclear Mechanistic DGIdb
SITRAVATINIB ↓ inhibits Mechanistic DGIdb
ONO-7579 ? unclear Mechanistic DGIdb
IMATINIB ? unclear Mechanistic DGIdb
ALISERTIB ? unclear Mechanistic DGIdb
CYTARABINE ? unclear Mechanistic DGIdb
REPOTRECTINIB ↓ inhibits Mechanistic DGIdb
ZIDESAMTINIB ↓ inhibits Mechanistic DGIdb
SURAMIN ? unclear Mechanistic DGIdb
PLX7486 ? unclear Mechanistic DGIdb
AZD-6918 ↓ inhibits Mechanistic DGIdb
ASPIRIN ? unclear Mechanistic DGIdb
CZS-241 ↓ inhibits Mechanistic DGIdb
RADICICOL ? unclear Mechanistic DGIdb
LEVOTHYROXINE SODIUM ? unclear Mechanistic DGIdb
LESTAURTINIB ↓ inhibits Mechanistic DGIdb
PILOCARPINE HYDROCHLORIDE ? unclear Mechanistic DGIdb

Showing top 40 of 256 agents ranked by evidence tier.

PDCD1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CAMRELIZUMAB ↓ inhibits Mechanistic DGIdb
AMP-224 ? unclear Mechanistic DGIdb
PEMBROLIZUMAB ↓ inhibits Mechanistic DGIdb
SERPLULIMAB ? unclear Mechanistic DGIdb
ENLONSTOBART ? unclear Mechanistic DGIdb
CEMIPLIMAB ↓ inhibits Mechanistic DGIdb
CT-011 ? unclear Mechanistic DGIdb
SASANLIMAB ? unclear Mechanistic DGIdb
PUCOTENLIMAB ↓ inhibits Mechanistic DGIdb
TISLELIZUMAB ? unclear Mechanistic DGIdb
TEBOTELIMAB ↓ inhibits Mechanistic DGIdb
CADONILIMAB ? unclear Mechanistic DGIdb
SPARTALIZUMAB ? unclear Mechanistic DGIdb
MEDI0680 ? unclear Mechanistic DGIdb
AUNP-12 ? unclear Mechanistic DGIdb
DOSTARLIMAB ? unclear Mechanistic DGIdb
TORIPALIMAB ↓ inhibits Mechanistic DGIdb
CC-90006 ? unclear Mechanistic DGIdb
CETRELIMAB ↓ inhibits Mechanistic DGIdb
PROGRAMMED CELL DEATH 1 LIGAND 1 ? unclear Mechanistic DGIdb
ANTI-PD-1 MONOCLONAL ANTIBODY SYM021 ? unclear Mechanistic DGIdb
CS-1003 ↓ inhibits Mechanistic DGIdb
EZABENLIMAB ? unclear Mechanistic DGIdb
PROLGOLIMAB ? unclear Mechanistic DGIdb
LIPUSTOBART ? unclear Mechanistic DGIdb
PENPULIMAB ↓ inhibits Mechanistic DGIdb
BALSTILIMAB ? unclear Mechanistic DGIdb
GEPTANOLIMAB ? unclear Mechanistic DGIdb
IVONESCIMAB ? unclear Mechanistic DGIdb
SINTILIMAB ? unclear Mechanistic DGIdb
LORIGERLIMAB ? unclear Mechanistic DGIdb
FINOTONLIMAB ↓ inhibits Mechanistic DGIdb
RETIFANLIMAB ? unclear Mechanistic DGIdb
PUCOLENTIMAB ? unclear Mechanistic DGIdb
BINTRAFUSP ALFA ? unclear Mechanistic DGIdb
IPAROMLIMAB ? unclear Mechanistic DGIdb
PIMIVALIMAB ↓ inhibits Mechanistic DGIdb
VUDALIMAB ? unclear Mechanistic DGIdb
APL-501 ↓ inhibits Mechanistic DGIdb
ZIMBERELIMAB ↓ inhibits Mechanistic DGIdb

Showing top 40 of 52 agents ranked by evidence tier.

RET

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
SNS-314 ? unclear Mechanistic DGIdb
KBP-7018 ↓ inhibits Mechanistic DGIdb
PONATINIB ↓ inhibits Mechanistic DGIdb
TYROSINE KINASE INHIBITOR ? unclear Mechanistic DGIdb
TAMATINIB ↓ inhibits Mechanistic DGIdb
GW441756X ? unclear Mechanistic DGIdb
SORAFENIB ↓ inhibits Mechanistic 13.0 nM (Kd) DGIdb
AMUVATINIB ↓ inhibits Mechanistic DGIdb
LENVATINIB ↓ inhibits Mechanistic DGIdb
REGORAFENIB ↓ inhibits Mechanistic DGIdb
PRALSETINIB ↓ inhibits Mechanistic DGIdb
SUNITINIB ↓ inhibits Mechanistic 12.0 nM (Kd) DGIdb
SELPERCATINIB ↓ inhibits Mechanistic DGIdb
NVP-TAE684 ? unclear Mechanistic DGIdb
RESENCATINIB ↓ inhibits Mechanistic DGIdb
SORAFENIB TOSYLATE ↓ inhibits Mechanistic DGIdb
LUCITANIB ↓ inhibits Mechanistic DGIdb
CABOZANTINIB S-MALATE ↓ inhibits Mechanistic DGIdb
IMATINIB ? unclear Mechanistic DGIdb
DOVITINIB ? unclear Mechanistic 71.0 nM (Kd) DGIdb
TRETINOIN ? unclear Mechanistic DGIdb
CP-547632 ? unclear Mechanistic DGIdb
MOTESANIB ↓ inhibits Mechanistic 14.0 nM (Kd) DGIdb
TETRADECANOYLPHORBOL ACETATE ? unclear Mechanistic DGIdb
ILORASERTIB ? unclear Mechanistic DGIdb
ENTRECTINIB ? unclear Mechanistic DGIdb
PD166285 ? unclear Mechanistic DGIdb
HESPERADIN ↓ inhibits Mechanistic DGIdb
RECOMBINANT CHEMOKINE ? unclear Mechanistic DGIdb
RET INHIBITOR TY-1091 ? unclear Mechanistic DGIdb
CEP-2563 DIHYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
RET INHIBITOR FHND5071 ? unclear Mechanistic DGIdb
VOLASERTIB ? unclear Mechanistic DGIdb
TAFETINIB ↓ inhibits Mechanistic DGIdb
TOZASERTIB ↓ inhibits Mechanistic 28.0 nM (Kd) DGIdb
PALBOCICLIB ? unclear Mechanistic DGIdb
SB220025 ? unclear Mechanistic DGIdb
ALISERTIB ? unclear Mechanistic DGIdb
AZD1480 ? unclear Mechanistic DGIdb
COMPOUND 8H [PMID: 21561767] ↓ inhibits Mechanistic DGIdb

Showing top 40 of 233 agents ranked by evidence tier.

ROS1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TALETRECTINIB ↓ inhibits Mechanistic DGIdb
CRIZOTINIB ↓ inhibits Mechanistic 4.1 nM (Kd) DGIdb
CERITINIB ? unclear Mechanistic 141.8 nM (IC50) DGIdb
SNS-314 ? unclear Mechanistic 1584.89 nM (Ki) DGIdb
LORLATINIB ↓ inhibits Mechanistic DGIdb
REPOTRECTINIB ↓ inhibits Mechanistic DGIdb
CABOZANTINIB S-MALATE ? unclear Mechanistic DGIdb
JNJ-7706621 ? unclear Mechanistic 501.19 nM (Ki) DGIdb
PROCYSTEINE ? unclear Mechanistic DGIdb
PEMBROLIZUMAB ? unclear Mechanistic DGIdb
ILORASERTIB ? unclear Mechanistic 5.012 nM (Ki) DGIdb
NEFLAMAPIMOD ? unclear Mechanistic 398.11 nM (Ki) DGIdb
RG-1530 ? unclear Mechanistic 19.95 nM (Ki) DGIdb
ALISERTIB ? unclear Mechanistic 158.49 nM (Ki) DGIdb
CEMIPLIMAB ? unclear Mechanistic DGIdb
BATOPROTAFIB ? unclear Mechanistic DGIdb
CP-547632 ? unclear Mechanistic DGIdb
ALECTINIB ? unclear Mechanistic DGIdb
AST-487 ? unclear Mechanistic 1700.0 nM (Kd) DGIdb
ERLOTINIB ? unclear Mechanistic DGIdb
HESPERADIN ↓ inhibits Mechanistic 77.0 nM (Kd) DGIdb
GEFITINIB ? unclear Mechanistic DGIdb
ALK/C-MET INHIBITOR TQ-B3139 ? unclear Mechanistic DGIdb
GILTERITINIB ↓ inhibits Mechanistic DGIdb
SB202190 ? unclear Mechanistic DGIdb
AFATINIB ? unclear Mechanistic DGIdb
PF-562271 ? unclear Mechanistic DGIdb
ZIDESAMTINIB ? unclear Mechanistic DGIdb
CARBOPLATIN ? unclear Mechanistic DGIdb
FORETINIB ? unclear Mechanistic 14.0 nM (Kd) DGIdb
TAFENOQUINE ? unclear Mechanistic DGIdb
OSIMERTINIB ? unclear Mechanistic DGIdb
IRUPLINALKIB ? unclear Mechanistic DGIdb
AZD3463 ? unclear Mechanistic DGIdb
COMPOUND 8E [PMID: 24432909] ↓ inhibits Mechanistic DGIdb
PACLITAXEL PROTEIN-BOUND ? unclear Mechanistic DGIdb
MLN-8054 ? unclear Mechanistic 3100.0 nM (Kd) DGIdb
ENTRECTINIB ↓ inhibits Mechanistic DGIdb
TOZASERTIB ? unclear Mechanistic 610.0 nM (Kd) DGIdb
TAMATINIB ? unclear Mechanistic DGIdb

Showing top 40 of 214 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Lung Cancer: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors Recruiting
NCT06747585 Phase: 1/2 Started: 2024-12-16

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 as a monotherapy or in combination with pembrolizumab in adult patients with selected squamous so...

A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy Recruiting
NCT06931717 Phase: 3 Started: 2026-01-12

ARCH is a randomised, stratified, multicentre, phase III trial. Protocol treatment consists of cemiplimab, 350 mg i.v., every 3 weeks, for 4 cycles, followed by 700 mg i.v., every 6 weeks for 6 cycles or until relapse or unacceptable toxicities, whichever occurs first. The primary objective of the s...

Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive Recruiting
NCT07063329 Phase: 1/2 Started: 2025-08-22

Tyrosine Kinase Inhibitor (TKI) that targets Epidermal Growth Factor Receptor (EGFR) mutations. Unfortunately, despite the benefit observed for patients treated with EGFR-TKI, the vast majority of cancers are expected to develop resistance to the drug over time. The exact reasons why resistance deve...

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) Recruiting
NCT07502300 Phase: 3 Started: 2026-06-15

This trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of BL-B01D1 in combination with tislelizumab versus platinum-based chemotherapy in combination with tislelizumab in first-line patients with extensive-stage small cell lung cancer.

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain Recruiting
NCT06741085 Phase: 2 Started: 2024-12-13

The researchers are doing this study is to find out whether treating brain metastasis with SRS after 3 months of therapy with osimertinib is better than treating with osimertinib alone in people with NSCLC. The researchers will also look at how the study intervention impacts participants' quality of...

A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) Recruiting
NCT07465757 Phase: 2 Started: 2026-09-17

The goal of this clinical trial is to determine how well people tolerate treatment with alisertib at different doses when it is used together with paclitaxel to treat people with SCLC. The main question it aims to answer is: * What percentage of side effects, both mild and serious, do participants e...

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer Completed
NCT03999710 Phase: 2 Started: 2019-07-19

The purpose of this study is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy.

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC Recruiting
NCT06627647 Phase: 3 Started: 2024-11-27

The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC whose tumors express PD-L1.

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy Recruiting
NCT07472517 Phase: 3 Started: 2026-04-13

This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an an...

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors Recruiting
NCT07080242 Phase: 1 Started: 2025-04-28

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms

A Platform Study in Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT06996782 Phase: 1/2 Started: 2025-11-24

The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study Recruiting
NCT07295821 Phase: 2 Started: 2026-04-01

The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent RT and maintenance osimertinib in chemotherapy ineligible or refusal adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).

Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT07149649 Phase: 2/3 Started: 2026-09-29

This study investigates whether adding magnesium to the standard chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC) can improve treatment outcomes. Magnesium is important for immune function, and low levels during chemotherapy are common. Participants are randomly assigned to receiv...

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations Recruiting
NCT06357533 Phase: 3 Started: 2024-04-11

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (T...

Tarlatamab for SCLC Brain Metastases Recruiting
NCT07402343 Phase: 2 Started: 2026-08-10

A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).

Agents Found By Disease-Level Search

Searched directly from “Lung Cancer” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 12-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

52 agents shown (approved or with trial evidence) — 39 not found by the gene-target search above.

Carboplatin

Phase 3 · 6 trials · source: ClinicalTrials.gov, Open Targets
NCT02364999 NCT02142738 NCT02367781

Pembrolizumab

Phase 3 · 5 trials · source: ClinicalTrials.gov, Open Targets
NCT02432963 NCT05269381 NCT02142738

docetaxelNOT in gene-target list

Phase 3 · 5 trials · source: ClinicalTrials.gov, Open Targets
NCT00003565 NCT00620971 NCT00620971

Bevacizumab

Phase 3 · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT06307249 NCT00620971 NCT00620971

Cisplatin

Phase 3 · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT02142738 NCT00620971 NCT00620971

PaclitaxelNOT in gene-target list

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT02364999 NCT02142738 NCT00998192

Nivolumab

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT06735781 NCT07246863 NCT04300244

Tremelimumab

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT02000947 NCT02000947

Atezolizumab

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT03526900 NCT06077500

PemetrexedNOT in gene-target list

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT02142738 NCT02367781

Gemcitabine

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT02142738 NCT00620971

cetuximab

Phase 1 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT05355701 NCT00251498

Etoposide

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT06077500 NCT01642251

TrilaciclibNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT06698965 NCT05874401

ripretinib (DCC-2618)NOT in gene-target list

Approved · 2 trials · source: ClinicalTrials.gov
NCT02571036 NCT02571036

YSCH-01NOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT07793500 NCT07793500

Modified Vaccinia Virus Ankara Vaccine Expressing p53NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02432963

entinostat

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02437136

serplulimab (HLX10)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04063163

carboplatin and etoposideNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04063163

Cisplatin, ThiosulfateNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01114958

VATS lobectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04799509

Bevacizumab-PfizerNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02364999

Bevacizumab-EUNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02364999

HyperSightNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06236516

EthosNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06236516

LurbinectedinNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT05285033

Immune Killer Cells (IKC)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03515252

custirsen sodiumNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00138658

ABX Combined With CisplatinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01810367

Gemcitabine Combined With CisplatinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01810367

temozolomide

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00022711

Gefitinib

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00357734

INCB099280NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04242199

gold sodium thiomalateNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00575393

gene expression analysisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00575393

ULD CTNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04482114

Tubeless anesthesiaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07024433

Traditional tracheal intubationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07024433

durvalumab (MEDI4736)NOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov
NCT02000947

CyclophosphamideNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT05269381

Neoantigen Peptide VaccineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05269381

SargramostimNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT05269381

Computed TomographyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05269381

MetoprololNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01281787

LosartanNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01281787

Gefitinib 250mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01530334

SNPNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06307249

Palbociclib 125mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06307249

Erlotinib (Tarceva)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00440414

Pemetrexed (Alimta)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00440414

4 cycles of Serplulimab combined with etoposide and carboplatin or cisplatinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06911606

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.